venetoclax with decitabine for high-risk aml and mds
Published 4 years ago • 654 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
5:36
venetoclax and azacitidine in mds patients
-
2:08
venetoclax-based quadruplet therapy with trametinib for patients with ras-mutated aml and mds
-
6:21
decitabine and venetoclax for aml
-
2:16
rationale for 10-day decitabine with venetoclax for high-risk aml
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
12:05
venetoclax combinations, safety and efficacy
-
5:52
the power of venetoclax
-
3:28
preclinical studies of tasquinimod in mds: in vitro and in vivo investigations
-
8:54
venetoclax plus azacitidine in treatment-naïve higher-risk mds
-
3:17
venetoclax with azacitidine in hr-mds
-
0:47
tamibarotene combined with azacitidine and venetoclax to treat aml and mds with rara abnormalities
-
5:52
venetoclax in combination with azacitidine for patients with treatment-naïve hr-mds
-
6:58
venetoclax plus azacitidine for higher-risk mds
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
1:41
novel therapies for high-risk mds
-
0:45
oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with aml
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml
-
1:48
azacitidine and venetoclax maintenance post allosct in high-risk t-all
-
4:04
venetoclax plus azacitidine in treatment-naïve hr-mds
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:50
treating patients with poor-risk cytogenetics with venetoclax and hmas